NCT01481272 2021-12-27
PLRG8
Polish Lymphoma Research Group
Phase 2 Completed
Clinical Trials
7 trialsNCT01626352 2017-11-22
Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02412267 2016-03-23
DLBL
National Cancer Centre, Singapore
Phase 2 Completed
NCT01014208 2015-08-07
ORCHARRD
GlaxoSmithKline
Phase 3 Completed
NCT00622388 2015-07-24
Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant
GlaxoSmithKline
Phase 2 Completed
NCT01397591 2014-07-30
Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00823719 2013-03-12
Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)
GlaxoSmithKline
Phase 2 Completed